BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11299770)

  • 1. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
    Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.
    Andersson H; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
    Acta Oncol; 2000; 39(6):741-5. PubMed ID: 11130014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
    Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
    Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
    Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
    Larsen RH; Bruland OS; Hoff P; Alstad J; Lindmo T; Rofstad EK
    Radiat Res; 1994 Aug; 139(2):178-84. PubMed ID: 8052693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
    Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
    Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.